Navigation Links
Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
Date:10/31/2007

CRANBURY, N.J., Oct. 31 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (AMEX: PTN) announced today the initiation of dosing in a Phase 1 clinical trial of PL-3994, a long acting analog of atrial natriuretic peptide, under development for treatment of acute decompensated congestive heart failure (CHF). The trial is being conducted under an Investigational New Drug application Palatin submitted to the U.S. Food and Drug Administration. Future plans include the development of PL-3994 for long term administration in patients with chronic congestive heart failure.

The Phase 1 trial of PL-3994 is a randomized, double-blind, placebo- controlled, single-ascending dose study in healthy volunteers who will receive the drug subcutaneously. The evaluations will include safety, tolerability, pharmacokinetics and several pharmacodynamic endpoints, including endogenous messenger levels such as cyclic guanosine monophosphate.

Dr. Trevor Hallam, Palatin's Executive Vice President for Research and Development, stated, "We are excited to begin clinical trials of PL-3994, a compound developed by Palatin scientists that has the potential to become a new tool for physicians to advance the treatment of congestive heart failure. CHF is the single most common cause of hospitalization in the U.S. for patients older than 65 years of age and an underserved medical condition."

Atrial natriuretic peptide (ANP) is a naturally produced peptide hormone involved in regulation of water and sodium levels in the circulation. Palatin's PL-3994 is a peptidomimetic compound, which incorporates features of both natural ANP and small molecules.

Preclinical studies have demonstrated that PL-3994 is highly potent. Its longer duratio
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
2. Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction
3. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...cal Incorporated (Nasdaq: VICL ) announced today...rom Merck & Co., Inc. based on Merck,s planned...stigational plasmid DNA (pDNA) cancer vaccine. The...livery technology and encodes human telomerase rev...f separate license agreement. , , "The brea...
(Date:11/28/2008)...- Eli Lilly and Company,(NYSE: LLY ) has withdr...rom,the U.S. Food and Drug Administration (FDA) f...t of chronic pain. Lilly plans to resubmit the app...rom a recently completed positive study,in chroni...cision does not affect duloxetine,s FDA-approved i...
(Date:11/26/2008)...KLIN, Mass., Nov. 26 PLC...d today that it has received full approval from th...U.S. pivotal trial to study the effectiveness of t... therapy in the prevention of Contrast-Induced Nep...LC,s request to expand their investigation from th...
(Date:11/25/2008)...re/ -- Proteolix, Inc., a,leader in the discovery...,protein degradation pathways in cancer and autoi...o ongoing Phase 2 clinical trials of carfilzomib i...ing 50th Annual Meeting of the,American Society o... new class,of specific proteasome inhibitors and ...
Breaking Medicine Technology:Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3LI COR Biosciences and Euthanex Corporation Provide Anesthesia System for Small Animal Imaging 8527 1LI COR Biosciences and Euthanex Corporation Provide Anesthesia System for Small Animal Imaging 8527 2DFG continues to strengthen biodiversity research 5543 1DFG continues to strengthen biodiversity research 5543 2Innovative strategies for war wounded 5538 1Innovative strategies for war wounded 5538 2Field hospital on a chip project awarded to nanoengineer from UC San Diego 5536 1Field hospital on a chip project awarded to nanoengineer from UC San Diego 5536 2Field hospital on a chip project awarded to nanoengineer from UC San Diego 5536 3
...lso Support Drug,s Efficacy at Improving Glycemic ...ications, CHICAGO, Ill., June 23, 2007 /PRNewswire...mercialization partner S2 Therapeutics,Inc., repo...trial,supporting the overall and cardiovascular sa...of bromocriptine mesylate) in subjects,with type 2...
...R CITY, Calif.--(BUSINESS WIRE)--June 25, 2007--Gi...that Study 103, a,Phase III clinical trial evaluat...R) (tenofovir disoproxil fumarate or tenofovir,DF)...itis B virus,(HBV) infection, met its primary effi...ferior to the company,s once-daily antiviral,drug ...
Other Medicine Technology:Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 2Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 3Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 4Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 6
(Date:12/1/2008)...wire-USNewswire/ -- In recognition of World AIDS D...ching a mobile texting campaign to raise money for... a program of the Safe Blood for Africa Foundation...e million lives in Africa by 2011 by working in re...cal training. , , OMALI will be collecting...
(Date:12/1/2008)...RNewswire/ -- TOMS Shoes, the philanthropic,footw...e at TOMSshoes.com,encouraging people to Spend L...s, from November 20th through December 20th, TOMS ...irs of shoes to children in Ethiopia suffering,fr... by wearing shoes. By,purchasing a pair of shoes ...
(Date:12/1/2008)...rom U-M physician include economical options , ...SNewswire/ -- A bottle of cologne, a new pair of p...s to buy and wrap for the upcoming holiday season....y and beneficial to a loved one? Why not give the ... the holidays can be challenging, and this year, m...
(Date:12/1/2008)...swire/ -- TorreyPines Therapeutics, Inc.,(Nasdaq:... of NGX426, an,AMPA/kainate-type glutamate recept...ficant reduction in spontaneous pain, hyperalgesia...(pain resulting from normally non-painful stimuli ...ermal injections of capsaicin in,a human experime...
Breaking Medicine News(10 mins):Health News:In Recognition of WORLD AIDS DAY, Charlotte Bobcats' Power Forward, Emeka Okafor, Launches Mobile Texting Campaign in Support of the One Million African Lives Initiative 2Health News:TOMS Shoes Embarks on a Holiday Mission: Give 30,000 Pairs in 30 Days! 2Health News:Giving the Gift of Health This Holiday Season 2Health News:Giving the Gift of Health This Holiday Season 3Health News:Giving the Gift of Health This Holiday Season 4Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 2Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 3Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 4Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 5
...terday about a surgeon Dr Jerome Blanchard who had.../ her with only a diseased one. The disciplinary...hurry removed the wrong kidney from a patient and ...did not bother to read her medical notes. Dr Jerom...
... price tag attached to it.Look at the United State...ealth and opportunity to its people;// but at a co...are 30% Americans who areover-weight or grossly ob...beingmade by China is going to land the country in...
...ude as many patients in the chronic disease manage...ter for Health Khaw Boon Wan who was addressing he...at chronic diseases are major causes of death and ...he past," Khaw said, adding that prompt treatment ...
...everages by the FDA (Food and Drug Administration)...nce of benzene//, a carcinogen in much higher amou...inking water. FDA had alerted these companies, an...te the soft drinks or had already done so. Though ...
Other Medicine News:Health News:Consultant Bungles A Kidney Surgery 2Health News:The Price Paid for New Lifestyle 2Health News:Soda Drinks Contain Benzene - A Carcinogen, Reports FDA 2Health News:Soda Drinks Contain Benzene - A Carcinogen, Reports FDA 3
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
Medicine Products: